BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish

Published on 09/23/2026 at 12:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock closed at $63.94 on September 18, 2026, while J.P. Morgan kept an $86 target. Second-quarter EPS beat estimates by $0.25.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical Inc. (US09061G1013) closed at USD 63.94 on September 18, 2026, on the Nasdaq, with a daily change of 0.00 percent. The biotech company's latest reported quarter delivered EPS of USD 1.20, or USD 0.25 above the USD 0.95 consensus estimate, while revenue increased 20.0 percent year over year, according to MarketBeat in its September 2026 overview.

Analyst target stays above price

J.P. Morgan maintained a Buy rating and an USD 86.00 price target in a report published on September 22, 2026, according to The Globe and Mail. The target is USD 22.06 above the September 18 closing price, a difference of about 34.5 percent based on those two figures.

The same September 22 report cited an average analyst target of USD 93.15 and described consensus as Strong Buy. It also said TipRanks upgraded the stock to Buy with a USD 72.00 target on September 14, 2026, giving investors a lower reference point than J.P. Morgan's target.

Quarterly earnings provide support

BioMarin reported its latest quarterly earnings on August 6, 2026. EPS of USD 1.20 exceeded consensus by USD 0.25, and revenue rose 20.0 percent from the comparable period, according to MarketBeat. The earnings surprise is the clearest quantified operating comparison currently attached to the share story.

The market data also show a wide trading range. BioMarin changed hands between USD 49.26 and USD 70.98 over the cited 52-week period, while the September 18 volume was 4.46 million shares against an average volume of 1.84 million shares, according to the same MarketBeat stock overview. The closing price was therefore USD 7.04 below the reported 52-week high.

Stock remains below yearly high

BioMarin Pharmaceutical stock closed at USD 63.94 on the Nasdaq on September 18, 2026, with the reported market capitalization at USD 12.38 billion. The stock's valuation data included a price-to-earnings ratio of 172.81 and no dividend yield in the cited market snapshot.

The next earnings date was listed as October 26, 2026, in the MarketBeat calendar. That date is an estimated calendar entry rather than a confirmed company reporting announcement, so the next quarterly figures remain the more important scheduled checkpoint for the earnings narrative.